CompletedNCT07038876
ML-007C-MA for schizophrenia
This study is completed in the United States. It is testing ML-007C-MA for schizophrenia.
In United StatesSchizophreniaDrugA study involving a medication or substance.From 18 Years to 64 Years
Study directory
Back to overviewMental health studies with practical context.
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
TerminatedNCT04855747
REL-1017 for depression
This study was terminated in the United States. It is testing REL-1017 for depression.
In United StatesDepressionDrugFrom 18 Years to 65 Years
CompletedNCT05972044
Solriamfetol for ADHD
This study is completed in the United States. It is testing solriamfetol for ADHD.
In United StatesADHDDrugFrom 18 Years to 55 Years
CompletedNCT06285916
Safety study of Efficacy, Safety, and Tolerability of Oral NORA520 in depression
This study is completed in the United States. It is testing Efficacy, Safety, and Tolerability of Oral NORA520 for depression.
In United StatesDepressionDrugFrom 18 Years to 45 Years
CompletedNCT01559272
Safety study of pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in schizophrenia
This study is completed in the United States, in Belgium, in Bulgaria, .... It is testing pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate for schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 65 Years
CompletedNCT01530529
Relative Bioavailability of a Modified-Release Formulation of PF-05180999
This study is completed in the United States. It focuses on Schizophrenia.
In United StatesSchizophreniaDrugFrom 18 Years to 55 Years
CompletedNCT05059600
Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
This study is completed in the United States. It is testing Safe-Use Conditions for Depression.
Remote / onlineDepressionDrugOver 18 Years
CompletedNCT03557931
Safety and Efficacy of ASP4345 for schizophrenia
This study is completed in the United States. It is testing Safety and Efficacy of ASP4345 for schizophrenia.
Remote / onlineSchizophreniaDrugFrom 18 Years to 55 Years
CompletedNCT06979544
Safety study of Safety and Efficacy of Oral LPCN 1154A in Depression
This study is completed in the United States. It is testing Safety and Efficacy of Oral LPCN 1154A for Depression.
In United StatesDepressionDrugFrom 15 Years to 45 Years
CompletedNCT03665038
Brexanolone for depression
This study is completed in the United States. It is testing brexanolone for depression.
In United StatesDepressionDrugFrom 15 Years to 17 Years
CompletedNCT03818256
Safety study of safety, Efficacy, and Pharmacokinetics of Miricorilant in schizophrenia
This study is completed in the United States. It is testing safety, Efficacy, and Pharmacokinetics of Miricorilant for schizophrenia.
In United StatesBipolarity, SchizophreniaDrugFrom 18 Years to 65 Years
CompletedNCT00812058
Safety study of Safety, Tolerability and Efficacy of RG2417 in depression
This study is completed in the United States. It is testing Safety, Tolerability and Efficacy of RG2417 for depression.
In United StatesBipolarity, DepressionDrugFrom 18 Years to 65 Years
Public registry coverage is progressing
HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.